Tyrosine Kinase Inhibitor
Tuspetinib for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Sacramento, California
This trial is testing a new drug, HM43239, for patients with relapsed or refractory acute myeloid leukemia (AML). The goal is to find the safe dose range and to see how well the drug works.
Anti-tumor antibiotic
BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Recruiting1 awardPhase 1
New York, New York
"This trial is studying a new drug for people with relapsed or refractory acute myelogenous leukemia or higher-risk myelodysplastic syndrome. The study has two phases: Phase 1
Popular Filters
Trials for Megakaryoblastic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for Acute Promyelocytic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for FLT3 Positive Patients
Chemotherapy
Ziftomenib Combinations for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Greenville, South Carolina
This trial will test the safety and effectiveness of a drug called ziftomenib when used together with standard treatments for patients with a type of blood cancer called acute myeloid leukemia that has come back
CAR T-cell Therapy
Genetically Modified T-cell Therapy for Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial is testing the side effects and best dosage of genetically modified T-cells, which are a type of immune cell, in patients with leukemia or a certain type of cancer of the blood and bone marrow.
Nucleoside Metabolic Inhibitor
Nintedanib + Azacitidine for Acute Myeloid Leukemia
Recruiting3 awardsPhase 1
Chicago, Illinois
This trial is testing a new drug, nintedanib, to see if it is effective in treating AML in older adults who cannot have standard intensive chemotherapy. The side effects of the combination will also be studied.
Anti-metabolite
Sorafenib + Chemotherapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial tests the best dose of sorafenib combined with busulfan and fludarabine for patients with hard-to-treat acute myeloid leukemia. Sorafenib blocks enzymes needed for cancer growth, while busulfan and fludarabine kill or stop the spread of cancer cells. Sorafenib has shown potential in early studies for treating acute myeloid leukemia.
Trials for CD33 Positive Patients
Anti-tumor antibiotic
Daunorubicin-Cytarabine + Gemtuzumab for Acute Myeloid Leukemia
Recruiting1 awardPhase 2
Houston, Texas
This trial is studying the side effects and effectiveness of two drugs, liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin, in treating patients with relapsed or refractory acute myeloid leukemia or high risk myelodysplastic syndrome.
CAR T-cell Therapy
CD33 CART Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new treatment for leukemia that uses the patient's own immune cells. The first part of the trial will test how safe it is, and the second part will test how well it works.
Phase 3 Trials
DNA Methyltransferase Inhibitor
DFP-10917 for Acute Myeloid Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing an experimental treatment called DFP-10917 against standard treatments for relapsed or refractory acute myeloid leukemia (AML). Patients in the experimental arm will receive DFP-10917 by continuous intravenous infusion for 14 days, followed by a 14-day resting period, for up to 6 cycles. Patients in the control arm will receive standard treatments, which may include non-intensive reinduction or intensive reinduction, depending on the patient's prior induction treatment.
Chemotherapy
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
Recruiting1 awardPhase 3
Winnipeg, Manitoba
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
Radioimmunotherapy
Iomab-B + HCT for Acute Myeloid Leukemia
Recruiting2 awardsPhase 3
Gilbert, Arizona
This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.
BCL-2 Inhibitor
Venetoclax + Azacitidine for Acute Myeloid Leukemia
Recruiting1 awardPhase 3
Duarte, California
This trial is testing a new combination treatment for acute myeloid leukemia (AML), a cancer of the blood and bone marrow. The treatment consists of the experimental drug venetoclax, which kills cancer cells by blocking a protein that allows them to stay alive, combined with azacitidine. The study will enroll approximately 400 participants globally and will compare the efficacy of the new combination treatment to azacitidine alone.
Trials With No Placebo
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.